RxDoctor Payments Data

Samir Bhatt, MD

Interventional Cardiology · Santa Maria, CANPI 1295925972

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $242,406 of the $322,750 with a category attached, or 75.1%. Amgen accounts for 60.2% of it on its own, with 41 other manufacturers making up the rest. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$322,750in general payments, 2019–2025

Across 912 payments — averaging $353.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$194K
  • Esperion Therapeutics, Inc.$45K
  • Sanofi-aventis U.S. LLC$23K
  • Johnson & Johnson$13K
  • Boston Scientific$12K
  • Regeneron Healthcare Solutions, Inc.$11K
  • plus $26K from 36 others

What the payments were for

  • Speaking & faculty fees$242,40675%
  • Travel & lodging$51,55816%
  • Food & beverage$28,7359%
  • Education$510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$322,750 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$383,065
Medicare patients
792
Services billed
4,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab285$309,825
EliquisApixaban170$224,205
XareltoRivaroxaban154$196,682
EntrestoSacubitril/Valsartan46$56,819
Praluent PenAlirocumab36$37,097
VascepaIcosapent Ethyl47$31,676
JardianceEmpagliflozin24$28,140
BrilintaTicagrelor36$26,103
NexlizetBempedoic Acid/Ezetimibe20$21,991
NexletolBempedoic Acid24$20,285
Ezetimibe513$19,464
Icosapent Ethyl36$12,169
VerquvoVericiguat11$8,446
Metoprolol Succinate365$6,545
Rosuvastatin Calcium319$5,414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$139$224,205170 claims
Johnson & JohnsonXarelto$12,580$196,682154 claims
NovartisEntresto$677$56,81946 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$44,616$42,27644 claims
Boehringer IngelheimJardiance$1,181$28,14024 claims
AstraZenecaBrilinta$291$26,10336 claims
MerckVerquvo$558$8,44611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Santa Maria

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →